Bluebird whistles up $100M; Anacor shares boosted by FDA approval; Portola collaborates with Daiichi Sankyo on PhIII;

@FierceBiotech: AstraZeneca spreads its virtual reach to cardio R&D with new partnership. News | Follow @FierceBiotech

@JohnCFierce: Intent on closing a deal, AbbVie boosts its bid for Shire to $51B. News | Follow @JohnCFierce

@DamianFierce: So $SHPG has 10 days to consider $ABBV's +11% offer. Press release | Follow @DamianFierce

@EmilyMFierce: European neuroscientists ask for better governance and tough review in EU Human Brain Project. Science story | Follow @EmilyMFierce

> Cambridge, MA-based bluebird bio ($BLUE) has filed to raise $100 million in a public offering. The biotech has been building a reputation in gene therapy and gene engineering. Release

> Shares of Palo Alto, CA-based Anacor Pharmaceutical ($ANAC) were buoyed by news of the FDA's approval of Kerydin, its new treatment for fungal infections of the nail. Release

> The FDA granted a priority review for Purdue Pharma's abuse-resistant hydrocodone pain tablet. The news dented shares of Zogenix ($ZGNX), which is facing competition for its own controversial pain therapy. Release

> South San Francisco-based Portola Pharmaceuticals ($PTLA) struck a collaboration deal with Daiichi Sankyo to study its experimental andexanet alfa with Daiichi Sankyo's Factor Xa inhibitor edoxaban. Release

> The rare-disease biotech UltraGenyx ($RARE) plans to offer a bit more than 2 million shares for sale. The offering from the Novato, CA-based biotech includes 706,072 shares from its investors. Release

> Raptor Pharmaceuticals announced that Julie Anne Smith, EVP and COO, has been named president and CEO-designate. Release

Medical Device News

@FierceMedDev: ICYMI yesterday: FDA lowers regulatory bar for neurostimulators to treat headache. Story | Follow @FierceMedDev

@StacyALawrence: Boston Scientific backs Israeli cardio device startup Mvalve with $15M. More | Follow @StacyALawrence

@VarunSaxena2: Check out our special report on the top 10 highest paid med tech CEOs. Feature | Follow @VarunSaxena2

@MichaelGFierce: A tiny, "walking" robot powered by a muscle cell? It could help deliver drugs one day. FierceDrugDelivery story | Follow @MichaelGFierce

@EmilyWFierce: Rapid Dx tests for Chagas disease yield quick, reliable results without lab confirmation, according to study. New York Times article | Follow @EmilyWFierce

> Researchers develop realtime, 'nanojuice'-enabled imaging method for gut. Report

> Ulthera device clears FDA for décolleté on heels of Merz acquisition plans. News

> Surgeons tout benefits of Google Glass in operating room. Article

Pharma News

@FiercePharma: Top-read on FP Monday: EU approves GSK's Mekinist and Novartis will reap the rewards. Article | Follow @FiercePharma

@EricPFierce: Health Canada tells GSK to get its vaccine house in order as flu season approaches. Story | Follow @EricPFierce

@CarlyHFierce: ICYMI: Ackman puts forth his slate of new Allergan directors. Report | Follow @CarlyHFierce

> AbbVie puts $51.5B on the table in fourth go at Shire. More

> Novartis accused again of kickback tactics in new whistleblower suit. Report

> Merck attacks Italian critic of cholesterol fighter Zetia, then backs off. Article

Biotech Research News

> Schizophrenia-linked genetic variation causes abnormal brain cell development. More

> Blocking cell migration could stop cancer spread. Article

> Technique regrows corneas in mice from adult human stem cells. Story

> Chemical switch could be drug target for neurodegenerative disease. More

> AstraZeneca, MRC Technology renew preclinical pact. Item

Pharma Manufacturing News

> Cipla plans U.K. investment as Indian drugmakers await economic reforms. More

> Ingredient price hikes prompt Express Scripts to slash coverage of compounded drugs. Story

> Novo A/S-owned Xellia snaps up Fresenius vial plant to expand in U.S. Report

> Hospira completes Orchid plant takeover to boost API supply security. Item

> Ingredient price hikes prompt Express Scripts to slash coverage of compounded drugs. Story

> Health Canada gives GSK 30 days to show how it will fix its vaccine plant. Article